Global Histoplasmosis Treatment Market

Histoplasmosis Treatment Comprehensive Study by Application (Hospitals Pharmacies, Private clinics, Drug stores and retail pharmacy, E-commerce), Drugs (Amphotericin B, Itraconazole, Ketoconazole, Other), Medication (Oral Medication, Injection-based) Players and Region - Global Market Outlook to 2030

Histoplasmosis Treatment Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Histoplasmosis Treatment
Histoplasmosis is an infection caused by inhaling spores of the fungus Histoplasma capsulatum. Histoplasmosis is a fungal infection that can be found all over the world. In the soil, the Histoplasma fungus grows as a mould. This fungus is commonly found in soil that has been contaminated by bat or bird droppings. People with weakened immune systems are more vulnerable and are more likely to be infected or reactivated with histoplasmosis. People who are very young, elderly, or suffering from cancer, AIDS, or organ transplant usually have severe symptoms. People suffering from chronic lung diseases such as bronchiectasis or emphysema are at a high risk of experiencing severe pain. Fever, chills, cough, chest pain, red skin bumps, mouth sores, and other symptoms of histoplasmosis are common. Histoplasmosis may spread throughout the body and cause irritation and swelling in some patients in response to infection. Certain symptoms include chest pain caused by swelling in the heart lining, neck stiffness, and so on. A biopsy of the lungs, skin, liver, or bone marrow is usually used to diagnose the disease. Certain blood and urine tests can also detect histoplasmosis proteins or antibodies in the body. In some cases, doctors will also perform a Chest CT scan, Chest X-ray, Bronchoscopy, and other tests.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Histoplasmosis Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Bristol Myers Squibb (United States), Sigma tau pharmaceuticals Inc. (United States), Three rivers pharmaceuticals (United States), Astellas pharma US Inc. (Japan), Abbott laboratories (United States), Abraxis BioScience (United States), Teva parenteral medicines Inc. (United States) and X gen pharmaceuticals Inc. (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Histoplasmosis Treatment market by , Application (Hospitals Pharmacies, Private clinics, Drug stores and retail pharmacy and E-commerce) and Region.



On the basis of geography, the market of Histoplasmosis Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drugs, the sub-segment i.e. Amphotericin B will boost the Histoplasmosis Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Medication, the sub-segment i.e. Oral Medication will boost the Histoplasmosis Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing concerns with aging health problems

Market Growth Drivers:
Increasing number of an aging population and Increasing prevalence of AIDS or organ failure

Challenges:
Unawareness in many regions

Restraints:
Cost and critical reimbursement scenarios

Opportunities:
Increasing investment by the government and public organizations to provide better healthcare quality

Market Leaders and their expansionary development strategies
In January 2019, Australia-based Mayne Pharma launched of TOLSURA (SUBA®-itraconazole) 65mg capsule in the United States. TOLSURA is a new formulation of itraconazole indicated for the treatment of systemic fungal infections including blastomycosis (pulmonary and extrapulmonary), histoplasmosis (including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis) and aspergillosis (pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy).
In August 2021, the Central Drugs Standard Control Organization (CDSCO) provided its nod to a major pharmaceutical company, Glenmark Pharma for the manufacturing and marketing of Itraconazole Capsules 130mg. They are indicated for the treatment of specified fungal infections in immune-compromised and non-immunocompromised adult patients.


Key Target Audience
Histoplasmosis Treatment Providers, Hospitals, Laboratory, Government & Research Organisation, End-Use Industry and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Hospitals Pharmacies
  • Private clinics
  • Drug stores and retail pharmacy
  • E-commerce
By Drugs
  • Amphotericin B
  • Itraconazole
  • Ketoconazole
  • Other

By Medication
  • Oral Medication
  • Injection-based

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing number of an aging population
      • 3.2.2. Increasing prevalence of AIDS or organ failure
    • 3.3. Market Challenges
      • 3.3.1. Unawareness in many regions
    • 3.4. Market Trends
      • 3.4.1. Increasing concerns with aging health problems
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Histoplasmosis Treatment, by Application, Drugs, Medication and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Histoplasmosis Treatment (Value)
      • 5.2.1. Global Histoplasmosis Treatment by: Application (Value)
        • 5.2.1.1. Hospitals Pharmacies
        • 5.2.1.2. Private clinics
        • 5.2.1.3. Drug stores and retail pharmacy
        • 5.2.1.4. E-commerce
      • 5.2.2. Global Histoplasmosis Treatment by: Drugs (Value)
        • 5.2.2.1. Amphotericin B
        • 5.2.2.2. Itraconazole
        • 5.2.2.3. Ketoconazole
        • 5.2.2.4. Other
      • 5.2.3. Global Histoplasmosis Treatment by: Medication (Value)
        • 5.2.3.1. Oral Medication
        • 5.2.3.2. Injection-based
      • 5.2.4. Global Histoplasmosis Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Histoplasmosis Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bristol Myers Squibb (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sigma tau pharmaceuticals Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Three rivers pharmaceuticals (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Astellas pharma US Inc. (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Abbott laboratories (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Abraxis BioScience (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Teva parenteral medicines Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. X gen pharmaceuticals Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Histoplasmosis Treatment Sale, by Application, Drugs, Medication and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Histoplasmosis Treatment (Value)
      • 7.2.1. Global Histoplasmosis Treatment by: Application (Value)
        • 7.2.1.1. Hospitals Pharmacies
        • 7.2.1.2. Private clinics
        • 7.2.1.3. Drug stores and retail pharmacy
        • 7.2.1.4. E-commerce
      • 7.2.2. Global Histoplasmosis Treatment by: Drugs (Value)
        • 7.2.2.1. Amphotericin B
        • 7.2.2.2. Itraconazole
        • 7.2.2.3. Ketoconazole
        • 7.2.2.4. Other
      • 7.2.3. Global Histoplasmosis Treatment by: Medication (Value)
        • 7.2.3.1. Oral Medication
        • 7.2.3.2. Injection-based
      • 7.2.4. Global Histoplasmosis Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Histoplasmosis Treatment: by Application(USD Million)
  • Table 2. Histoplasmosis Treatment Hospitals Pharmacies , by Region USD Million (2018-2023)
  • Table 3. Histoplasmosis Treatment Private clinics , by Region USD Million (2018-2023)
  • Table 4. Histoplasmosis Treatment Drug stores and retail pharmacy , by Region USD Million (2018-2023)
  • Table 5. Histoplasmosis Treatment E-commerce , by Region USD Million (2018-2023)
  • Table 6. Histoplasmosis Treatment: by Drugs(USD Million)
  • Table 7. Histoplasmosis Treatment Amphotericin B , by Region USD Million (2018-2023)
  • Table 8. Histoplasmosis Treatment Itraconazole , by Region USD Million (2018-2023)
  • Table 9. Histoplasmosis Treatment Ketoconazole , by Region USD Million (2018-2023)
  • Table 10. Histoplasmosis Treatment Other , by Region USD Million (2018-2023)
  • Table 11. Histoplasmosis Treatment: by Medication(USD Million)
  • Table 12. Histoplasmosis Treatment Oral Medication , by Region USD Million (2018-2023)
  • Table 13. Histoplasmosis Treatment Injection-based , by Region USD Million (2018-2023)
  • Table 14. South America Histoplasmosis Treatment, by Country USD Million (2018-2023)
  • Table 15. South America Histoplasmosis Treatment, by Application USD Million (2018-2023)
  • Table 16. South America Histoplasmosis Treatment, by Drugs USD Million (2018-2023)
  • Table 17. South America Histoplasmosis Treatment, by Medication USD Million (2018-2023)
  • Table 18. Brazil Histoplasmosis Treatment, by Application USD Million (2018-2023)
  • Table 19. Brazil Histoplasmosis Treatment, by Drugs USD Million (2018-2023)
  • Table 20. Brazil Histoplasmosis Treatment, by Medication USD Million (2018-2023)
  • Table 21. Argentina Histoplasmosis Treatment, by Application USD Million (2018-2023)
  • Table 22. Argentina Histoplasmosis Treatment, by Drugs USD Million (2018-2023)
  • Table 23. Argentina Histoplasmosis Treatment, by Medication USD Million (2018-2023)
  • Table 24. Rest of South America Histoplasmosis Treatment, by Application USD Million (2018-2023)
  • Table 25. Rest of South America Histoplasmosis Treatment, by Drugs USD Million (2018-2023)
  • Table 26. Rest of South America Histoplasmosis Treatment, by Medication USD Million (2018-2023)
  • Table 27. Asia Pacific Histoplasmosis Treatment, by Country USD Million (2018-2023)
  • Table 28. Asia Pacific Histoplasmosis Treatment, by Application USD Million (2018-2023)
  • Table 29. Asia Pacific Histoplasmosis Treatment, by Drugs USD Million (2018-2023)
  • Table 30. Asia Pacific Histoplasmosis Treatment, by Medication USD Million (2018-2023)
  • Table 31. China Histoplasmosis Treatment, by Application USD Million (2018-2023)
  • Table 32. China Histoplasmosis Treatment, by Drugs USD Million (2018-2023)
  • Table 33. China Histoplasmosis Treatment, by Medication USD Million (2018-2023)
  • Table 34. Japan Histoplasmosis Treatment, by Application USD Million (2018-2023)
  • Table 35. Japan Histoplasmosis Treatment, by Drugs USD Million (2018-2023)
  • Table 36. Japan Histoplasmosis Treatment, by Medication USD Million (2018-2023)
  • Table 37. India Histoplasmosis Treatment, by Application USD Million (2018-2023)
  • Table 38. India Histoplasmosis Treatment, by Drugs USD Million (2018-2023)
  • Table 39. India Histoplasmosis Treatment, by Medication USD Million (2018-2023)
  • Table 40. South Korea Histoplasmosis Treatment, by Application USD Million (2018-2023)
  • Table 41. South Korea Histoplasmosis Treatment, by Drugs USD Million (2018-2023)
  • Table 42. South Korea Histoplasmosis Treatment, by Medication USD Million (2018-2023)
  • Table 43. Taiwan Histoplasmosis Treatment, by Application USD Million (2018-2023)
  • Table 44. Taiwan Histoplasmosis Treatment, by Drugs USD Million (2018-2023)
  • Table 45. Taiwan Histoplasmosis Treatment, by Medication USD Million (2018-2023)
  • Table 46. Australia Histoplasmosis Treatment, by Application USD Million (2018-2023)
  • Table 47. Australia Histoplasmosis Treatment, by Drugs USD Million (2018-2023)
  • Table 48. Australia Histoplasmosis Treatment, by Medication USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Histoplasmosis Treatment, by Application USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Histoplasmosis Treatment, by Drugs USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Histoplasmosis Treatment, by Medication USD Million (2018-2023)
  • Table 52. Europe Histoplasmosis Treatment, by Country USD Million (2018-2023)
  • Table 53. Europe Histoplasmosis Treatment, by Application USD Million (2018-2023)
  • Table 54. Europe Histoplasmosis Treatment, by Drugs USD Million (2018-2023)
  • Table 55. Europe Histoplasmosis Treatment, by Medication USD Million (2018-2023)
  • Table 56. Germany Histoplasmosis Treatment, by Application USD Million (2018-2023)
  • Table 57. Germany Histoplasmosis Treatment, by Drugs USD Million (2018-2023)
  • Table 58. Germany Histoplasmosis Treatment, by Medication USD Million (2018-2023)
  • Table 59. France Histoplasmosis Treatment, by Application USD Million (2018-2023)
  • Table 60. France Histoplasmosis Treatment, by Drugs USD Million (2018-2023)
  • Table 61. France Histoplasmosis Treatment, by Medication USD Million (2018-2023)
  • Table 62. Italy Histoplasmosis Treatment, by Application USD Million (2018-2023)
  • Table 63. Italy Histoplasmosis Treatment, by Drugs USD Million (2018-2023)
  • Table 64. Italy Histoplasmosis Treatment, by Medication USD Million (2018-2023)
  • Table 65. United Kingdom Histoplasmosis Treatment, by Application USD Million (2018-2023)
  • Table 66. United Kingdom Histoplasmosis Treatment, by Drugs USD Million (2018-2023)
  • Table 67. United Kingdom Histoplasmosis Treatment, by Medication USD Million (2018-2023)
  • Table 68. Netherlands Histoplasmosis Treatment, by Application USD Million (2018-2023)
  • Table 69. Netherlands Histoplasmosis Treatment, by Drugs USD Million (2018-2023)
  • Table 70. Netherlands Histoplasmosis Treatment, by Medication USD Million (2018-2023)
  • Table 71. Rest of Europe Histoplasmosis Treatment, by Application USD Million (2018-2023)
  • Table 72. Rest of Europe Histoplasmosis Treatment, by Drugs USD Million (2018-2023)
  • Table 73. Rest of Europe Histoplasmosis Treatment, by Medication USD Million (2018-2023)
  • Table 74. MEA Histoplasmosis Treatment, by Country USD Million (2018-2023)
  • Table 75. MEA Histoplasmosis Treatment, by Application USD Million (2018-2023)
  • Table 76. MEA Histoplasmosis Treatment, by Drugs USD Million (2018-2023)
  • Table 77. MEA Histoplasmosis Treatment, by Medication USD Million (2018-2023)
  • Table 78. Middle East Histoplasmosis Treatment, by Application USD Million (2018-2023)
  • Table 79. Middle East Histoplasmosis Treatment, by Drugs USD Million (2018-2023)
  • Table 80. Middle East Histoplasmosis Treatment, by Medication USD Million (2018-2023)
  • Table 81. Africa Histoplasmosis Treatment, by Application USD Million (2018-2023)
  • Table 82. Africa Histoplasmosis Treatment, by Drugs USD Million (2018-2023)
  • Table 83. Africa Histoplasmosis Treatment, by Medication USD Million (2018-2023)
  • Table 84. North America Histoplasmosis Treatment, by Country USD Million (2018-2023)
  • Table 85. North America Histoplasmosis Treatment, by Application USD Million (2018-2023)
  • Table 86. North America Histoplasmosis Treatment, by Drugs USD Million (2018-2023)
  • Table 87. North America Histoplasmosis Treatment, by Medication USD Million (2018-2023)
  • Table 88. United States Histoplasmosis Treatment, by Application USD Million (2018-2023)
  • Table 89. United States Histoplasmosis Treatment, by Drugs USD Million (2018-2023)
  • Table 90. United States Histoplasmosis Treatment, by Medication USD Million (2018-2023)
  • Table 91. Canada Histoplasmosis Treatment, by Application USD Million (2018-2023)
  • Table 92. Canada Histoplasmosis Treatment, by Drugs USD Million (2018-2023)
  • Table 93. Canada Histoplasmosis Treatment, by Medication USD Million (2018-2023)
  • Table 94. Mexico Histoplasmosis Treatment, by Application USD Million (2018-2023)
  • Table 95. Mexico Histoplasmosis Treatment, by Drugs USD Million (2018-2023)
  • Table 96. Mexico Histoplasmosis Treatment, by Medication USD Million (2018-2023)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Histoplasmosis Treatment: by Application(USD Million)
  • Table 106. Histoplasmosis Treatment Hospitals Pharmacies , by Region USD Million (2025-2030)
  • Table 107. Histoplasmosis Treatment Private clinics , by Region USD Million (2025-2030)
  • Table 108. Histoplasmosis Treatment Drug stores and retail pharmacy , by Region USD Million (2025-2030)
  • Table 109. Histoplasmosis Treatment E-commerce , by Region USD Million (2025-2030)
  • Table 110. Histoplasmosis Treatment: by Drugs(USD Million)
  • Table 111. Histoplasmosis Treatment Amphotericin B , by Region USD Million (2025-2030)
  • Table 112. Histoplasmosis Treatment Itraconazole , by Region USD Million (2025-2030)
  • Table 113. Histoplasmosis Treatment Ketoconazole , by Region USD Million (2025-2030)
  • Table 114. Histoplasmosis Treatment Other , by Region USD Million (2025-2030)
  • Table 115. Histoplasmosis Treatment: by Medication(USD Million)
  • Table 116. Histoplasmosis Treatment Oral Medication , by Region USD Million (2025-2030)
  • Table 117. Histoplasmosis Treatment Injection-based , by Region USD Million (2025-2030)
  • Table 118. South America Histoplasmosis Treatment, by Country USD Million (2025-2030)
  • Table 119. South America Histoplasmosis Treatment, by Application USD Million (2025-2030)
  • Table 120. South America Histoplasmosis Treatment, by Drugs USD Million (2025-2030)
  • Table 121. South America Histoplasmosis Treatment, by Medication USD Million (2025-2030)
  • Table 122. Brazil Histoplasmosis Treatment, by Application USD Million (2025-2030)
  • Table 123. Brazil Histoplasmosis Treatment, by Drugs USD Million (2025-2030)
  • Table 124. Brazil Histoplasmosis Treatment, by Medication USD Million (2025-2030)
  • Table 125. Argentina Histoplasmosis Treatment, by Application USD Million (2025-2030)
  • Table 126. Argentina Histoplasmosis Treatment, by Drugs USD Million (2025-2030)
  • Table 127. Argentina Histoplasmosis Treatment, by Medication USD Million (2025-2030)
  • Table 128. Rest of South America Histoplasmosis Treatment, by Application USD Million (2025-2030)
  • Table 129. Rest of South America Histoplasmosis Treatment, by Drugs USD Million (2025-2030)
  • Table 130. Rest of South America Histoplasmosis Treatment, by Medication USD Million (2025-2030)
  • Table 131. Asia Pacific Histoplasmosis Treatment, by Country USD Million (2025-2030)
  • Table 132. Asia Pacific Histoplasmosis Treatment, by Application USD Million (2025-2030)
  • Table 133. Asia Pacific Histoplasmosis Treatment, by Drugs USD Million (2025-2030)
  • Table 134. Asia Pacific Histoplasmosis Treatment, by Medication USD Million (2025-2030)
  • Table 135. China Histoplasmosis Treatment, by Application USD Million (2025-2030)
  • Table 136. China Histoplasmosis Treatment, by Drugs USD Million (2025-2030)
  • Table 137. China Histoplasmosis Treatment, by Medication USD Million (2025-2030)
  • Table 138. Japan Histoplasmosis Treatment, by Application USD Million (2025-2030)
  • Table 139. Japan Histoplasmosis Treatment, by Drugs USD Million (2025-2030)
  • Table 140. Japan Histoplasmosis Treatment, by Medication USD Million (2025-2030)
  • Table 141. India Histoplasmosis Treatment, by Application USD Million (2025-2030)
  • Table 142. India Histoplasmosis Treatment, by Drugs USD Million (2025-2030)
  • Table 143. India Histoplasmosis Treatment, by Medication USD Million (2025-2030)
  • Table 144. South Korea Histoplasmosis Treatment, by Application USD Million (2025-2030)
  • Table 145. South Korea Histoplasmosis Treatment, by Drugs USD Million (2025-2030)
  • Table 146. South Korea Histoplasmosis Treatment, by Medication USD Million (2025-2030)
  • Table 147. Taiwan Histoplasmosis Treatment, by Application USD Million (2025-2030)
  • Table 148. Taiwan Histoplasmosis Treatment, by Drugs USD Million (2025-2030)
  • Table 149. Taiwan Histoplasmosis Treatment, by Medication USD Million (2025-2030)
  • Table 150. Australia Histoplasmosis Treatment, by Application USD Million (2025-2030)
  • Table 151. Australia Histoplasmosis Treatment, by Drugs USD Million (2025-2030)
  • Table 152. Australia Histoplasmosis Treatment, by Medication USD Million (2025-2030)
  • Table 153. Rest of Asia-Pacific Histoplasmosis Treatment, by Application USD Million (2025-2030)
  • Table 154. Rest of Asia-Pacific Histoplasmosis Treatment, by Drugs USD Million (2025-2030)
  • Table 155. Rest of Asia-Pacific Histoplasmosis Treatment, by Medication USD Million (2025-2030)
  • Table 156. Europe Histoplasmosis Treatment, by Country USD Million (2025-2030)
  • Table 157. Europe Histoplasmosis Treatment, by Application USD Million (2025-2030)
  • Table 158. Europe Histoplasmosis Treatment, by Drugs USD Million (2025-2030)
  • Table 159. Europe Histoplasmosis Treatment, by Medication USD Million (2025-2030)
  • Table 160. Germany Histoplasmosis Treatment, by Application USD Million (2025-2030)
  • Table 161. Germany Histoplasmosis Treatment, by Drugs USD Million (2025-2030)
  • Table 162. Germany Histoplasmosis Treatment, by Medication USD Million (2025-2030)
  • Table 163. France Histoplasmosis Treatment, by Application USD Million (2025-2030)
  • Table 164. France Histoplasmosis Treatment, by Drugs USD Million (2025-2030)
  • Table 165. France Histoplasmosis Treatment, by Medication USD Million (2025-2030)
  • Table 166. Italy Histoplasmosis Treatment, by Application USD Million (2025-2030)
  • Table 167. Italy Histoplasmosis Treatment, by Drugs USD Million (2025-2030)
  • Table 168. Italy Histoplasmosis Treatment, by Medication USD Million (2025-2030)
  • Table 169. United Kingdom Histoplasmosis Treatment, by Application USD Million (2025-2030)
  • Table 170. United Kingdom Histoplasmosis Treatment, by Drugs USD Million (2025-2030)
  • Table 171. United Kingdom Histoplasmosis Treatment, by Medication USD Million (2025-2030)
  • Table 172. Netherlands Histoplasmosis Treatment, by Application USD Million (2025-2030)
  • Table 173. Netherlands Histoplasmosis Treatment, by Drugs USD Million (2025-2030)
  • Table 174. Netherlands Histoplasmosis Treatment, by Medication USD Million (2025-2030)
  • Table 175. Rest of Europe Histoplasmosis Treatment, by Application USD Million (2025-2030)
  • Table 176. Rest of Europe Histoplasmosis Treatment, by Drugs USD Million (2025-2030)
  • Table 177. Rest of Europe Histoplasmosis Treatment, by Medication USD Million (2025-2030)
  • Table 178. MEA Histoplasmosis Treatment, by Country USD Million (2025-2030)
  • Table 179. MEA Histoplasmosis Treatment, by Application USD Million (2025-2030)
  • Table 180. MEA Histoplasmosis Treatment, by Drugs USD Million (2025-2030)
  • Table 181. MEA Histoplasmosis Treatment, by Medication USD Million (2025-2030)
  • Table 182. Middle East Histoplasmosis Treatment, by Application USD Million (2025-2030)
  • Table 183. Middle East Histoplasmosis Treatment, by Drugs USD Million (2025-2030)
  • Table 184. Middle East Histoplasmosis Treatment, by Medication USD Million (2025-2030)
  • Table 185. Africa Histoplasmosis Treatment, by Application USD Million (2025-2030)
  • Table 186. Africa Histoplasmosis Treatment, by Drugs USD Million (2025-2030)
  • Table 187. Africa Histoplasmosis Treatment, by Medication USD Million (2025-2030)
  • Table 188. North America Histoplasmosis Treatment, by Country USD Million (2025-2030)
  • Table 189. North America Histoplasmosis Treatment, by Application USD Million (2025-2030)
  • Table 190. North America Histoplasmosis Treatment, by Drugs USD Million (2025-2030)
  • Table 191. North America Histoplasmosis Treatment, by Medication USD Million (2025-2030)
  • Table 192. United States Histoplasmosis Treatment, by Application USD Million (2025-2030)
  • Table 193. United States Histoplasmosis Treatment, by Drugs USD Million (2025-2030)
  • Table 194. United States Histoplasmosis Treatment, by Medication USD Million (2025-2030)
  • Table 195. Canada Histoplasmosis Treatment, by Application USD Million (2025-2030)
  • Table 196. Canada Histoplasmosis Treatment, by Drugs USD Million (2025-2030)
  • Table 197. Canada Histoplasmosis Treatment, by Medication USD Million (2025-2030)
  • Table 198. Mexico Histoplasmosis Treatment, by Application USD Million (2025-2030)
  • Table 199. Mexico Histoplasmosis Treatment, by Drugs USD Million (2025-2030)
  • Table 200. Mexico Histoplasmosis Treatment, by Medication USD Million (2025-2030)
  • Table 201. Research Programs/Design for This Report
  • Table 202. Key Data Information from Secondary Sources
  • Table 203. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Histoplasmosis Treatment: by Application USD Million (2018-2023)
  • Figure 5. Global Histoplasmosis Treatment: by Drugs USD Million (2018-2023)
  • Figure 6. Global Histoplasmosis Treatment: by Medication USD Million (2018-2023)
  • Figure 7. South America Histoplasmosis Treatment Share (%), by Country
  • Figure 8. Asia Pacific Histoplasmosis Treatment Share (%), by Country
  • Figure 9. Europe Histoplasmosis Treatment Share (%), by Country
  • Figure 10. MEA Histoplasmosis Treatment Share (%), by Country
  • Figure 11. North America Histoplasmosis Treatment Share (%), by Country
  • Figure 12. Global Histoplasmosis Treatment share by Players 2023 (%)
  • Figure 13. Global Histoplasmosis Treatment share by Players (Top 3) 2023(%)
  • Figure 14. Global Histoplasmosis Treatment share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Bristol Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 17. Bristol Myers Squibb (United States) Revenue: by Geography 2023
  • Figure 18. Sigma tau pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Sigma tau pharmaceuticals Inc. (United States) Revenue: by Geography 2023
  • Figure 20. Three rivers pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 21. Three rivers pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 22. Astellas pharma US Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 23. Astellas pharma US Inc. (Japan) Revenue: by Geography 2023
  • Figure 24. Abbott laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 25. Abbott laboratories (United States) Revenue: by Geography 2023
  • Figure 26. Abraxis BioScience (United States) Revenue, Net Income and Gross profit
  • Figure 27. Abraxis BioScience (United States) Revenue: by Geography 2023
  • Figure 28. Teva parenteral medicines Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Teva parenteral medicines Inc. (United States) Revenue: by Geography 2023
  • Figure 30. X gen pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. X gen pharmaceuticals Inc. (United States) Revenue: by Geography 2023
  • Figure 32. Global Histoplasmosis Treatment: by Application USD Million (2025-2030)
  • Figure 33. Global Histoplasmosis Treatment: by Drugs USD Million (2025-2030)
  • Figure 34. Global Histoplasmosis Treatment: by Medication USD Million (2025-2030)
  • Figure 35. South America Histoplasmosis Treatment Share (%), by Country
  • Figure 36. Asia Pacific Histoplasmosis Treatment Share (%), by Country
  • Figure 37. Europe Histoplasmosis Treatment Share (%), by Country
  • Figure 38. MEA Histoplasmosis Treatment Share (%), by Country
  • Figure 39. North America Histoplasmosis Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Bristol Myers Squibb (United States)
  • Sigma tau pharmaceuticals Inc. (United States)
  • Three rivers pharmaceuticals (United States)
  • Astellas pharma US Inc. (Japan)
  • Abbott laboratories (United States)
  • Abraxis BioScience (United States)
  • Teva parenteral medicines Inc. (United States)
  • X gen pharmaceuticals Inc. (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 209 Pages 91 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Histoplasmosis Treatment Market Quantitative research analysis
Global Histoplasmosis Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Bristol Myers Squibb (United States), Sigma tau pharmaceuticals Inc. (United States), Three rivers pharmaceuticals (United States), Astellas pharma US Inc. (Japan), Abbott laboratories (United States), Abraxis BioScience (United States), Teva parenteral medicines Inc. (United States) and X gen pharmaceuticals Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing concerns with aging health problems" is seen as one of major influencing trends for Histoplasmosis Treatment Market during projected period 2023-2030.
The Histoplasmosis Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Histoplasmosis Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Animal Gelatin Capsule Comprehensive Study by Type (Hard Shelled Capsules, Soft Shelled Capsules), Application (Pharmaceuticals, Health Supplements, Cosmetics, Others), Origin (Bovine, Ovine, Caprine...
$ 3350
Drug Eluting Balloon Comprehensive Study by Type (Coronary, Peripheral, Urology, Others), Application (Hospitals, Others), Technology (FreePac, TransPac, EnduraCoat, Others), Material (Polyurethane, ...
$ 3350
Antidiarrheal Drugs Comprehensive Study by Type (OTC Drugs, Prescription Drugs, Others), Application (Adults, Children), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online, Others), Dru...
$ 3450
Mental Illness Drugs Comprehensive Study by Type (Antipsychotics, Antidepressants, Antianxiety (anxiolytics), Anti-seizure medications), Application (Hospital, Clinic, Drugstore), Distribution Channe...
$ 3750
Fish Vaccine Comprehensive Study by Type (Live, Inactivated, Subunit, DNA, Others), Application (Body in learning how to protect it from viruses), Administration (Oral, Immersion, Injected), Fish (Sa...
$ 3500
Dermatophytosis Drugs Comprehensive Study by Application (Superficial Antifungal Infections, Systemic Antifungal Infections), Route of Administration (Oral, Topical, Parenteral), Form (Powder, Ointme...
$ 3350